Saltar al contenido

Bonus Episode: Lessons from Early Adopters of XT in Schizophrenia with Ilan Melnick, MD

13 de octubre de 2026 · 54 min

Notas del episodio

In this bonus episode, host Ben Everett, PhD, reconnects with Ilan Melnick, MD, chief medical officer of Passageway, a South Florida forensic community control program, who also maintains a private concierge practice. Dr. Melnick chaired a JCP consensus panel of early adopters of xanomeline-trospium chloride (XT), and nearly two years after approval, he shares what clinicians have learned putting this first-in-class muscarinic agent into everyday practice.

Unlike dopamine D2 blockers, XT activates M1 and M4 muscarinic receptors to lower presynaptic dopamine, while trospium limits peripheral cholinergic effects. The conversation covers EMERGENT trial findings on positive, negative, and general psychopathology symptoms; early use in first-episode psychosis; titration to maintenance doses; prophylactic ondansetron and empty-stomach dosing; distinguishing cholinergic from anticholinergic adverse events; class-specific cross-titration; and antipsychotic dose sparing. Dr. Melnick also reviews two new Psych Congress posters: a real-world prescriber survey and a post hoc analysis of EMERGENT-5 examining GI side effects and treatment retention.

🎯 KEY EPISODE HIGHLIGHTS:

💊 ONDANSETRON BEFORE NAUSEA STARTS [31:00]

“One of the things we know about ondansetron is that it's a better preventer than it is a fixer.”

Prophylactic ondansetron at initiation is a simple step that can prevent early GI-related discontinuation.

⚖️ CHOLINERGIC OR ANTICHOLINERGIC? [36:00]

“If they're cholinergic in nature, go up to the one twenty-five. But if they're anticholinergic in nature then we have to see what other medicines are causing that extra anticholinergic effect.”

Identifying the type of adverse event determines whether to titrate up or review concomitant medications such as OTC sleep aids.

📈 STALLING AT 100 MG AND DROPOUT [49:41]

“So those that stay there and don't move up to the 125 milligram dose ended up usually dropping out due to higher GI issues.”

A post hoc EMERGENT-5 analysis suggests that titrating to the higher dose may support retention rather than threaten it.

CHAPTERS:

00:00 – Introduction: Revisiting the XT Consensus Panel

02:04 – Forensic Community Care and a Concierge Practice

05:26 – From Postsynaptic Blockade to Presynaptic Modulation

08:34 – M1/M4 Agonism and the Role of Trospium Chloride

13:03 – EMERGENT Trial Results and Early Cognitive Benefits

18:17 – Inside the Panel: Early Adopters and Experiential Evidence

22:35 – Early Use in First-Episode Psychosis and Dose Titration

28:28 – Patient Selection and Prophylactic Ondansetron

31:47 – Empty-Stomach Dosing and Cholinergic vs Anticholinergic Effects

37:15 – Cross-Titrating From Dones, Pines, and Partial Agonists

40:33 – Antipsychotic Dose Sparing, the ARISE Trial, and LAIs

44:17 – Psych Congress Poster: Real-World Prescriber Survey

49:07 – EMERGENT-5 Retention Data and the Future of Muscarinics

LINKS:

Full transcript and show notes:

https://www.psychiatrist.com/jcp/ep25-lessons-early-adopters-xt-schizophrenia-ilan-melnick/

Journal of Clinical Psychiatry

https://www.psychiatrist.com/jcp/

Publisher of peer-reviewed research discussed in this episode.

Real-World Implementation of Xanomeline-Trospium in Schizophrenia: A Consensus Panel Report

https://www.psychiatrist.com/jcp/real-world-implementation-xanomeline-trospium-schizophrenia-consensus-report/

The JCP consensus panel report chaired by Dr. Melnick and discussed throughout this episode.

Dr. Ilan Melnick - LinkedIn

https://www.linkedin.com/in/ilan-melnick-516b4468/

#Schizophrenia #XanomelineTrospium #MuscarinicAgonist #FirstEpisodePsychosis #Psychopharmacology

Todos los episodios de The Journal of Clinical Psychiatry Podcast

Ajustes

Visualización

Idioma

Determina qué emisoras ves primero en la página de inicio.

Historial

Las emisoras y episodios escuchados recientemente y tus últimas búsquedas solo se guardan en este navegador.

Avisos

Un breve aviso cuando un pódcast que sigues tiene un episodio nuevo. Puedes desactivar pódcast concretos con la campana de su página.

Cuenta

Guarda tus favoritos: en la app y en la web.

Atajos de teclado

/
Abrir búsqueda
Espacio
Reproducir o pausar
← →
En el reproductor: 15 s atrás, 30 s adelante (episodios) · en una fila: siguiente tarjeta
↑ ↓
En una fila: destino dentro de la tarjeta
Inicio / Fin
En una fila: primera o última tarjeta
Esc
Cerrar ventana o menú
?
Este resumen
Reproduciendo ahora

Ir a la emisora

A continuación

    Añade episodios con «A continuación»: sonarán después del episodio actual.